EVEREST MED.LTD DL-0001 Net Assets
EVEREST MED.LTD DL-0001 net assets. Based on the latest financial reports, EVEREST MED.LTD DL-0001 (6HN) has net assets worth €5.23 Billion EUR (≈ $6.11 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€8.45 Billion ≈ $9.87 Billion USD) and total liabilities (€3.22 Billion ≈ $3.76 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore EVEREST MED.LTD DL-0001 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €5.23 Billion |
| % of Total Assets | 61.92% |
| Annual Growth Rate | -2.6% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 18.7 |
Net Assets of EVEREST MED.LTD DL-0001 (2021–2025)
Net assets of EVEREST MED.LTD DL-0001 from 2021 to 2025. This chart illustrates how EVEREST MED.LTD DL-0001's net assets have evolved over time, based on quarterly financial data. See 6HN net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for EVEREST MED.LTD DL-0001 (2021–2025)
The table below shows the annual net assets of EVEREST MED.LTD DL-0001 from 2021 to 2025. For live market cap and overall valuation, see 6HN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €5.30 Billion ≈ $6.20 Billion |
+30.22% |
| 2024-12-31 | €4.07 Billion ≈ $4.76 Billion |
-18.03% |
| 2023-12-31 | €4.97 Billion ≈ $5.81 Billion |
-12.13% |
| 2022-12-31 | €5.65 Billion ≈ $6.61 Billion |
-4.03% |
| 2021-12-31 | €5.89 Billion ≈ $6.89 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to EVEREST MED.LTD DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 262942300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
EVEREST MED.LTD DL-0001 Net Assets Breakdown (December 2025)
EVEREST MED.LTD DL-0001 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €15.86 Billion | 298.99% |
| Total Equity | €5.30 Billion | 100.00% |
EVEREST MED.LTD DL-0001 Competitors by Market Cap
The table below lists competitors of EVEREST MED.LTD DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Donnelley Financial Solutions Inc
NYSE:DFIN
|
$1.16 Billion |
|
Guizhou Qianyuan Power Co Ltd
SHE:002039
|
$1.16 Billion |
|
Palfinger AG
VI:PAL
|
$1.17 Billion |
|
Fermi Inc.
NASDAQ:FRMI
|
$1.17 Billion |
|
Cymbria Corporation
TO:CYB
|
$1.16 Billion |
|
Darbond Technology Co. Ltd. A
SHG:688035
|
$1.16 Billion |
|
Shelly Group SE
XETRA:SLYG
|
$1.16 Billion |
|
Vizsla Silver Corp.
TO:VZLA
|
$1.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EVEREST MED.LTD DL-0001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,072,794,000 to 5,303,759,000, a change of 1,230,965,000 (30.2%).
- Net loss of 297,766,000 reduced equity.
- New share issuances of 1,448,763,000 increased equity.
- Other factors increased equity by 79,968,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-297.77 Million | -5.61% |
| Share Issuances | €1.45 Billion | +27.32% |
| Other Changes | €79.97 Million | +1.51% |
| Total Change | €- | 30.22% |
Book Value vs Market Value Analysis
This analysis compares EVEREST MED.LTD DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.19x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €20.01 | €2.84 | x |
| 2022-12-31 | €18.51 | €2.84 | x |
| 2023-12-31 | €15.56 | €2.84 | x |
| 2024-12-31 | €12.56 | €2.84 | x |
| 2025-12-31 | €15.01 | €2.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EVEREST MED.LTD DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.45%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.29x
- Recent ROE (-5.61%) is above the historical average (-13.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -17.12% | -1867998.15% | 0.00x | 1.13x | €-1.60 Billion |
| 2022 | -4.37% | -1933.11% | 0.00x | 1.17x | €-812.73 Million |
| 2023 | -17.00% | -670.57% | 0.02x | 1.16x | €-1.34 Billion |
| 2024 | -25.57% | -147.36% | 0.14x | 1.22x | €-1.45 Billion |
| 2025 | -5.61% | -17.45% | 0.25x | 1.29x | €-828.14 Million |
Industry Comparison
This section compares EVEREST MED.LTD DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $522,244,790
- Average return on equity (ROE) among peers: -61.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EVEREST MED.LTD DL-0001 (6HN) | €5.23 Billion | -17.12% | 0.61x | $1.16 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $120.33 Million |
| PreveCeutical Medical Inc (18H) | $-2.29 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $178.95 Million | -21.77% | 0.05x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $715.30 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.58 Million | -6.53% | 0.28x | $960.84K |
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocyc… Read more